Kymera Therapeutics, Inc. Common Stock
KYMR US5015751044
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3% | -61% | 2% | 59% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Jacobs Bruce N. CFO |
50.00 USD |
79,220 Sold |
3,961,380 USD |
17/09/2025 | 17/09/2025 |
| Mainolfi Nello CEO |
49.00 USD |
30,000 Sold |
1,470,000 USD |
16/09/2025 | 16/09/2025 |
| Ridloff Elena |
50.00 USD |
4,500 Sold |
225,000 USD |
11/06/2025 | 11/06/2025 |
| Ridloff Elena |
50.00 USD |
4,500 Sold |
225,000 USD |
11/06/2025 | 11/06/2025 |
| Albers Jeffrey W. |
49.00 USD |
6,349 Sold |
311,101 USD |
03/06/2025 | 03/06/2025 |
| Ridloff Elena |
45.50 USD |
7,200 Sold |
327,600 USD |
03/06/2025 | 03/06/2025 |
| Esposito Pamela |
49.04 USD |
5,000 Sold |
245,186 USD |
03/06/2025 | 03/06/2025 |
| Mainolfi Nello CEO |
49.00 USD |
30,000 Sold |
1,470,000 USD |
03/06/2025 | 03/06/2025 |
| Ridloff Elena |
47.00 USD |
4,800 Sold |
225,600 USD |
03/06/2025 | 03/06/2025 |
| Ridloff Elena |
47.00 USD |
4,800 Sold |
225,600 USD |
03/06/2025 | 03/06/2025 |